Phenylephrine is a direct alpha-1 adrenergic agonist, with weak alpha-2 adrenergic agonist activity. It also has very weak beta-adrenergic effects, but at therapeutic doses there are no significant stimulating beta-1 adrenergic effects on the heart, or on the bronchial airways, or on peripheral blood vessels. This contrasts with pseudoephedrine, which has greater beta-adrenergic activity. The effect on the alpha-adrenergic receptors leads to local vasoconstriction and shrinking of mucous membranes. There is no anti-histamine effect. The drug is readily and completely absorbed following oral administration, undergoing extensive first pass metabolism in the intestinal wall and in the liver leading to some variability in individual pharmacokinetics. Nasal decongestion is apparent within 15 to 20 minutes and persists for up to 4 hours (AHFS 2007).
Between 2001 and 2006 six human clinical trials with the hexadecapeptide AOD9604 have been performed, 893 healthy, in all but one study, clinically obese adults participated in these studies and are the basis of this safety evaluation. The details of the individual studies are listed in supplementary data. The first 3 studies were dose-escalating studies investigating the acute effects of various dosages and two application routes (i.v. and oral) in healthy or obese male subjects. These single dose studies were followed by a 7-day multiple dose study (METAOD004) as well as two long-term clinical trials (METAOD005 and METAOD006) where the safety and tolerability of chronic oral treatment with AOD9604 was investigated.
Two submissions were received, both in relation to AOD-9604. One submission did not comment on the scheduling proposal, but wished to inform the committee that the substance is an ingredient in cosmetic products being sold overseas, has an International Nomenclature Cosmetic Ingredient (INCI) name of 27701 sh-Oligopeptide-74 and is published in the International Cosmetic Ingredient Dictionary and Handbook as well as the International Buyer's Guide.
Another side effect of the CJC-1295 is acromegaly, since it helps in increasing the levels of the growth hormone. Acromegaly is a condition where extra growth hormone is released even after the internal organs and the skeleton have finished growing. This causes thickening of the skin, deepening of voice, enlargement of jaws, and slurring of speech. Another effect of acromegaly is the swelling of the soft tissue in the internal organs. This could result in the weakening of the muscles of the internal organs, like the heart. This was tested during the phase 2 testing of CJC-1295.
Your level of physical activity also affects IGF-1, and heavy weight training for your legs is a particularly potent way to increase it. Some studies suggest that the effects of the popular anti-aging supplement DHEA actually arise due to this same type of increase in IGF-1 in the body that occurs with with weight training (so you choose: heavy barbell squats or a bottle of DHEA from the drugstore).
Figure 2A shows that neither hGH nor AOD9604 had any significant effect on the weight of epididymal adipose tissue in the lean mice. However, in the ob/ob mice, AOD9604 induced a 28% decrease in epididymal adipose tissue mass, and hGH induced a 40% reduction in epididymal adipose tissue mass (P < 0.05). Brown adipose tissue weights were also measured (Fig. 2B). In this tissue, both AOD9604 and hGH induced a reduction in the weight of brown adipose tissue in both the lean and ob/ob mice.

Improved glucose metabolism after RYGB and sleeve gastrectomy involves several mechanisms: early increased hepatic insulin sensitivity, resulting from reduced liver fat content in response to the postoperative caloric restriction, improved beta-cell function mediated by exaggerated postprandial GLP-1 secretion; as demonstrated by relapse of impaired glucose tolerance in studies blocking the GLP-1 receptor by exendin 9–39, and later after major weight loss increased peripheral insulin sensitivity. Gut hormone secretion changes towards a more anorectic profile and is likely important for less caloric intake and weight loss.


GH levels decrease significantly as one ages. By the time you are 30 years old the endocrine system is no longer functioning optimally, thus the hormones that typically helped us stay lean, are secreting at a much lower level. The result of this is stubborn fat storage, which favours the abdominal region. Visceral fat in particular is a very common plight in middle age.
Best deal I found searching around. I plan to read up on datbtrue's forum once I get accepted. Right now I'm thinking wake up, and inject 500mcg, shower, hit the gym, leave do cardio, then eat. At night before bed inject another 500mcg. Not set in stone yet as I need to read up more, but this is what I'm thinking. Currently running cjc 1295 no dac, ghrp-2, and igf-1 LR3, Hup-a, and green tea extract.
AOD9604: AOD9604 is a synthetic peptide taken orally. The small peptide mimics a section of the growth hormone molecule which increases fat metabolism and decreases the production of fat. AOD9604 is claimed to reduce fat, increase muscle mass and possibly help recover from joint cartilage damage. However, there is currently no published human data to support these claims. AOD9604 is not approved for human use, but is used in sport for weight loss and muscle enhancement and the perception that it helps recover from tissue damage. This drug was highlighted in the Australian Crime Commission report on Organised Crime and Drugs in Sport. No significant adverse effects have been reported yet, but AOD9604 is now prohibited by WADA.
After the commencement of the active treatment 88.9% of subjects experienced at least one AE, whereby the distribution was similar in the 5 AOD9604 groups and the placebo group. There was a higher incidence (48.4%) of nervous system disorders (mainly headache, 42.6%), gastrointestinal disorders (30.4%, mainly diarrhea unspecified, 9.0%) and infections and infestations (45.3%), than seen before the commencement of active treatment. The distribution of the intensity of AEs was similar across all treatment groups. The percentage of AEs that deemed to be possibly or probably related to the study medication was similar across all treatment groups, including placebo.
Peptide therapy encompasses numerous different drugs with varied effects, ranging from immune modulation and tissue repair to fat loss and muscle building. Our center has seen very positive results in patients with CFS, Hashimoto’s thyroiditis, Lyme disease, and fibromyalgia, among other conditions. Ask your physician or speak to a patient representative at (877) 508-1177 to find out if peptide therapy is right for you.
I take or did take organic colostrum at the beginning of last year after starting a paleo food plan after having a gut issue and every day am and pm after a period off about 3 months started to have to pee during the night ( I’m 60) but never the dribble or straining just pee and then during the day 4-5 times a day rush to the toilet and pee for what seems ages
I have been using sermorelin (bioidentical growth hormone releasing hormone) for 2 months now to help heal a nasty right quad tendon rupture suffered the end of December. I’m 52 years old with 7% bodyfat and am a lifetime strength trainer and former high level bike racer. 2 months ago, in spite of months of religious rehab, I couldn’t do a single right leg bench stepup. Yesterday I was doing 20lb DB’s for repeated sets of 15. I get complete blood panels every 6 months, and my last labs in May showed my IGF-1 levels off the reference range low. I get my next bloods in a couple of weeks. I was initially afraid to try this hormone due to the cancer implications, and I didn’t need it to be lean and fit, but I was desperate and for my injury recovery, and it has made a significant difference. Plus, I believed supplementing the releasing hormone vs, IGF-1 limits the possibility of increasing the levels too much, as well as causing a negative feedback loop. By the way, I also tried TB-500 previous to the sermorelin, and it seemed to make some other achy joints in the gym go away, but didn’t seem to help the quad injury.
Studies have shown that individuals fighting infection have a lower amount of circulating T α 1 and suppressed helper T cell numbers compared to healthy individuals. This is problematic, as optimal immune function is vital to recovery from infection. Supplementation with T α 1 has the potential for great therapeutic benefit for patients suffering from infection or autoimmune disease.
The diet program combines medically scripted weight loss medication with specifically formulated Ketogenic supplements to help you control your appetite and switch your body into Ketosis – your body’s fat burning mode. The diet plan comes with a detailed booklet which steps your through the 30-day program, and includes a shopping list, recipes, KetoMed RX program specifics as well as other helpful resources.
Bremelanotide PT 141 was developed from Melanotan II, targeting its aphrodisiac effects. This peptide has been shown to have a substantial effect on libido, generating sexual arousal in both men and women within minutes of administration. It has been shown to be effective in treating erectile dysfunction, even in men who have not responded to other ED treatments, such as Viagara. This peptide is also able to cross the blood-brain-barrier, bypassing the vascular system and acting at the level of the central nervous system. This property gives Bremelanotide an advantage over traditional ED drugs, which can decrease blood pressure to dangerous levels. This peptide can be administered as a nasal spray, making its use convenient and discreet.
It is also important to note that whether you are a long-time user or a first-time user of Ipamorelin, your body is going to react differently to that of the next user. Like the benefits you will experience, the side effects you are going to experience will occur differently, and at different dosage levels. So, it truly is a trial and error period you are going to go through with a test run of Ipamorelin for new users. You have to find what works for you, how your body will react, and what potential side effects are lingering ahead, in order for you to achieve the greatest results, and eventually find the proper dosage and cycle level, which is going to work the best for your body and system.
CJC-1295 is a fast-acting Growth Hormone Releasing Hormone designed to enhance the body’s natural production and release of human growth hormone and Insulin-like Growth Factor 1 (IGF-1). In doing so, CJC-1295 reverses the age-related decline, generates new muscle cells and increases fat loss. Another great trait of CJC-1295 is its ability to promote slow wave sleep, a deep sleep responsible for the highest levels of cell regeneration, muscle growth and memory retention.

There are several limitations of our study. Given the nature of our physiologic protocols, which required two large volume saline infusions in obese patients before and after surgery, our sample size was modest. Nonetheless, we were able to elicit significant relationships of all four natriuretic peptides (ANP, Nt‐proANP, BNP, and Nt‐proBNP) across a variety of salt conditions before and after surgical weight loss. Our study population consisted of primarily females. We do not believe from prior epidemiologic studies looking at resting natriuretic peptide levels in obese individuals12 that having more men in our cohort would have modified our findings. Prior epidemiologic studies do not suggest that gender modifies the association between obesity and natriuretic peptide concentrations. We did not examine short‐term changes in the natriuretic peptide system, as a physiologic assessment immediately after surgery would have been impractical and potentially confounded by post‐operative shifts in volume or nutrition. We also focused on surgical weight loss because weight loss with non‐surgical treatments is less consistent. Thus, we cannot exclude any surgery‐specific effects. Because the saline infusion was indexed to BSA, less saline was given at the post‐weight loss visit. This could have created a “conservative” bias, eg, toward observing a smaller natriuretic peptide response after surgery. Indexing was performed to ensure that the amount of saline relative to plasma volume was relatively constant. Lastly, we did not perform a complete assessment of the renin‐angiotensin‐aldosterone system and the sympathetic nervous system, all of which could also be primarily affected resulting in the observed responses of the natriuretic peptide system after weight loss and/or saline loading.
The matters under subsection 52E (1) of the Therapeutic Goods Act 1989 considered relevant by the Committee included: a) the risks and benefits of the use of a substance; b) the purposes for which a substance is to be used and the extent of use of a substance; c) the toxicity of a substance; d) the dosage, formulation, labelling, packaging and presentation of a substance; and f) any other matters that the Secretary considers necessary to protect public health.

Figure 2A shows that neither hGH nor AOD9604 had any significant effect on the weight of epididymal adipose tissue in the lean mice. However, in the ob/ob mice, AOD9604 induced a 28% decrease in epididymal adipose tissue mass, and hGH induced a 40% reduction in epididymal adipose tissue mass (P < 0.05). Brown adipose tissue weights were also measured (Fig. 2B). In this tissue, both AOD9604 and hGH induced a reduction in the weight of brown adipose tissue in both the lean and ob/ob mice.


Obesity affects as many as one in five adults in developed countries. Metabolic estimates that the potential worldwide market for effective obesity drugs is as much as $20 billion, far more than the current market of $1.5 billion. This is partly due to the potential need for chronically obese people to take obesity drugs such as AOD9604 and also because patients are put off using currently available drugs because of their marginal efficacy or side-effects.
Cancer can often be a process of uncontrolled cellular division. IGF-1 is not only pro-growth in a way that could increase this cellular division, but IGF-1 also inhibits apoptosis, or programmed cell death. Hence the theory among some in the medical community that tumors could increase synthesis of IGF-1 to keep themselves alive and to encourage the spread of cancer throughout the body. This doesn’t mean that IGF-1 directly causes cancer.
176-191 peptide australian peptide australian peptides review australian peptide suppliers best hgh australia buy peptides online australia cjc-dac cjc 1295 ipamorelin Do Peptides Work for muscle building frag 176-191 ghrp6 cjc1295 hgh pills for sale in australia how do peptides work lr3 peptide melanotan 2 buy online australia melbourne sports medicine & anti-aging clinic Muscle Peptides Muscle Peptides Australia Review ostarine australia ostarine australia customs ostarine australia legal oxyshred australia reviews oxyshred flavour review oxyshred reviews 2018 oxyshred ultra concentrate review oxyshred weight loss results peptide clinic melbourne peptides australia peptides australia legal peptides direct legit peptides direct review peptides for sale in australia peptides melbourne peptides suppliers australia premium peptides australia research peptides bodybuilding SARMS Bodybuilding SARMS Dosage SARMS Side Effects who do peptides work for
But IGF-1 injections may soon be a thing of the past. Future use of IGF-1 will no doubt involve gene therapy, which directly targets genes that produce IGF-1 in muscle, usually by attaching specific gene activators to an inactive virus or vector that then enters into muscle cells. Studies in mice show that a procedure like this can cause  a 15% increase in muscle mass, along with a 14% increase in strength. Gene therapy in old mice has been shown to cause to a 27% increase in strength, along with regeneration of aging muscle. In one mouse study, the IGF-1 gene was placed in the animals’ glutes and calves, which resulted in up to a 115% increase in muscle-cross-sectional area.
The lateral and medial condyles of the femur and tibia were fixed with 10% neutral buffered formalin and decalcified with 20% ethylenediaminetetraacetic acid (EDTA). Calcified condyles were embedded in paraffin, and standard frontal sections of 5 μm were prepared and stained with haematoxylin and eosin in the cartilage of the lateral part of the femoral condyle, according to gross morphological observations [14]. If the staining was not adequate, the specimen was cut at the next cartilage surface. Cartilage degradation features were analyzed using the scoring system modified by Mankin et al. [14]. Histopathological evidence of cartilage degeneration was evaluated by structural scoring (0, normal; 1, surface irregularities; 2, pannus and surface irregularities; 3, clefts to transitional zones; 4, clefts to radial zones; 5, clefts to calcified zones; and 6, complete disorganization) and cell status (0, normal; 1, diffuse hypercellularity; 2, cloning; and 3, hypocellularity) of the articular cartilage. Total score ranged from 0 (normal) to 9 (complete disorganization and hypocellularity of the articular cartilage). All sections were graded by two independent pathologists who did not have any information about the injection solutions.
The acute effect of AOD9604 and BRL37344 (aβ 3-AR agonist) on energy expenditure and substrate oxidation rates in WT and KO mice was also assessed. KO animals had lower energy expenditure, lower fat oxidation, and increased glucose oxidation, compared with the WT controls (data not shown). Injection of WT mice with a single dose of BRL37344 or AOD9604 increased energy expenditure and fat oxidation and decreased glucose oxidation. In the KO animals, BRL37344 failed to elicit any response in these metabolic parameters, clearly demonstrating that its effects are mediated exclusively through the β3-AR. AOD9604 did elicit a response in the KO mice, increasing fat oxidation and energy expenditure, although the response was not as great as in WT mice, suggesting that β3-ARs are not responsible for the acute biological response of AOD9604 on lipid metabolism. This is consistent with our previous findings in which AOD9604 was shown not to bind to the β3-AR (11). The size and duration of the metabolic responses to AOD9604 in the β3-AR KO animals was different from that observed in the control wild-type mice. The response was more rapid, shorter in duration, and greater in peak response. This may be because the KO animals are more acutely sensitive to lipolytic agents, a compensation for the ablation of the major lipolytic receptor.
Thymosin beta-4 (TB-4): A naturally occurring protein found in blood platelets, TB-4 plays a role in the repair and regeneration of injured tissues in the human body. It was first detected in the thymus, a gland that produces white blood cells. While it’s recently been used to treat horses and implicated in horse doping, it’s also found its way into bodybuilding circles. While there is no published evidence that TB-4 produces any benefit to athletes, it was added to the WADA banned substances list in 2011.
Transparent Labs has gone back to the basics their PhysiqueSeries Fat Burner. This thermogenic weight-loss supplement focuses on the 3 keys of fat loss: increasing metabolism, preventing hunger cravings, and improving overall energy and pleasure from fat loss. Ingredients like ForsLean, green tea, and synephrine deliver clinically-proven ingredients to help you reach your goals. Read More
For Growth Hormone (GH) to perform its anabolic (muscle building) affects it requires the presence of the body's most anabolic hormone: insulin. This is in contrast to GH related fat loss which requires insulin to be absent. However, since GHRP and fast-acting GHRH (Growth Hormone Releasing Hormone) products (i.e. Modified GRF 1-29) still need time to stimulate the body to release GH from the pituitary gland, the insulin spike must come after the injection and not before, otherwise the GH release will be blunted.

The effects of hGH and AOD9604 on fat metabolism may be mediated by an alteration in the expression of a lipolytic/antilipogenic gene. Theβ 3-AR is a major lipolytic receptor identified in rodent fat cells (18) that mediates its effects through G protein coupling to adenylate cyclase, generation of cAMP, and stimulation of PKA (19). This enzyme then phosphorylates proteins in the lipolytic cascade, including hormone-sensitive lipase (20). In BAT, the β3-AR stimulates uncoupling of the electron transport chain, enhancing the ability of mitochondria to generate heat in preference to ATP through the dissipation of the electron gradient (21). Mice that lack this receptor have lower rates of resting energy expenditure (0.0041 vs. 0.0047 kcal/min, P < 0.02) and lower rates of fat oxidation (0.00019 vs. 0.00030 g/min, P < 0.02) than control mice (data not shown).


CJC-1295 is basically a peptide hormone that acts similar to growth hormone releasing hormones (GHRH). Invented by a Canadian biotechnology company called ConjuChem, it is beneficial to athletes because it can bioconjugate with circulating albumin and increase the time it can be used for medical purposes. It achieves this by preventing degradation of its amino acids. With a single dose, it can remain in the body for quite a few days and can cause the growth hormone to be released many times per day. This reduces the frequency of injections needed.
In the 80 years, scientists have searched different peptides and more particularly GHRH to discern what part was necessary to stimulate the pituitary response. Then in testing Sermorelin as a tool for the process of anti-agingthey found that it was the famous 1-29 chain that was responsible for stimulating the endocrine gland in question. Similarly, many studies have shown that this peptide was similar to GHRH and very well tolerated by the body.
With a blend of peptide and GH supplements, Ipamorelin can greatly help you in your weight loss endeavours. Using it with IGF-1 which is a natural growth hormone, can help you achieve even greater results. With lower dosage, you won’t increase muscle mass, your body will naturally decrease body fat levels, and you will begin to metabolize food faster, meaning you burn more calories in less time, for greater weight loss results.
PCR amplification was carried out on cDNA equivalent to 100 ng of starting mRNA using the following murine oligonucleotide primers (expected and observed PCR product size): β3-AR forward, 5′-TCTAGTTCCCAGCGGAGTTTTCATCG-3′; (234 bp) reverse, 5′-CGCGCACCTTCATAGCCATCAAACC-3′; β-actin forward, 5′-ATCCTGCGTCTGGACCTGGCTG-3′; (559 bp) reverse, 5′-CCTGCTTGCTGATCCACATCTGCTG-3′.
In 2010, the company heard word that bodybuilders were importing knock-off versions of the patent-protected peptide from China, and started licensing the manufacturing rights out to other companies in an attempt to compete, as this was determined to be a better course of action than attempting to sue the Chinese company for patent breach (7, 8). Desperate to recoup this investment, they invested a small additional amount into developing a technology that allowed the peptide to be absorbed through the skin, in collaboration with a company called Phosphagenics (4). The peptide was then licensed for use in BodyShaper, an anti-cellulite cream. Phosphagenics later dropped AOD9604 from BodyShaper, citing excessive expense and ineffectiveness (3).
However, both the original GRF (1-29) and the Mod GRF 1-29 required frequent dosages. So a new compound called CJC-1295 was created which was far more stable. This compound was made by adding Lysine – which is a non-peptide, and is also called Drug Affinity Complex or DAC. Since the original Mod GRF 1-29 does not contain DAC, it is named as CJC-1295 without DAC. However, the actual CJC-1295 is not only difficult, but also very expensive to produce. This is why it is not produced or used extensively. The Mod GRF 1-29 is far easier and cheaper to produce.

If there was a magic pill that could help improve digestion and gut health, erase wrinkles, ease joint pain and give you healthy, thick hair and nails, I would buy it by the truckload. After all, while boosting my overall health is a priority, having shinier hair and minimal crow’s feet is a major bonus. Although there’s no such magic pill, there is a supplement that promises these results and more—collagen peptides.
Prof. Louis J Aronne MD, President of the North American Association for the Study of Obesity and a member of Metabolic’s Clinical Advisory Panel, said: "This is an exciting new approach to a problem which has defied easy solutions. We will need many different treatments if we are going to manage obesity successfully, in much the same way we have many treatments available for diabetes and hypertension".
Muscle Peptides Australia strived to provide the highest quality peptide supplements available. Our research and development team work constantly to develop exclusive products that consistently outperform other supplements and brands on the market. We’ve specifically designed our products to assist in weight loss, muscle gain and increase injury recovery rates. Read more about what makes Muscle Peptides Australia the industry leaders in peptide supplements.
Our peptide therapies are also known as secretagogues – a substance that promotes secretion.  These amino acid chains communicate with the body to produce or release growth hormone.  The increased volume of human growth hormone produced by the pituitary gland causes an increase in the production of Insulin-Like Grow Factor-1 (IGF-1) by the liver and results in several health benefits such as:
One combination of natural supplements that boost IGF-1 with no injections required would simply be a one-two combo of whey protein and colostrum. Throw small bits of natural dairy into the mix and you’ve got a pretty potent trilogy for not just increasing IGF-1, but also all the fat loss, lean muscle gain, and cellular repair mechanisms that accompany a surge in growth hormone.
Smeath says he turns patients away on a weekly basis. "[Particularly] if a patient comes and asks me for a specific peptide and it's not right for them. It's the same as if an anti-biotic was unsuitable for a patient, we don't just prescribe it." He says a lot of people prefer face-to-face contact with the prescribing doctor, but if geography restricts them, phone and Skype sessions also take place.
×